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m etastatic melanoma: a m ulticentre phase II study
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Summary High response rates in patients with metastatic melanoma have been achieved with combination chemoimmunotherapy. A _ 
response rate of 62% in 45 patients has been reported for treatment with dacarbazine, bleomycin, vincristine, lomustine (BOLD) plus 
interferon a  (IFN-a). We conducted a multicentre phase II study to confirm these results. Melanoma patients with distant métastasés were 
treated as outpatients with dacarbazine 200 mg m-2 on days 1-5, vincristine 1 mg n r2 on days 1 and 4, bleomycin 15 mg on days 2 and 5 i.v. 
and lomustine 80 mg orally on day 1, repeated every 4 weeks. IFN-a-2b was initiated s.c. on day 8 at 3 MU daily for 6 weeks, and 6 MU t.i.w. 
thereafter. Forty-three patients entered the study. The median number of metastatic sites was three (range 1-5), and 81% of patients had 
visceral métastasés. Nine patients had brain métastasés, and seven patients were systemically pretreated. Among the 41 patients that were 
evaluable for response, the response rate was 27% (95% Cl 14-43%), with one complete and ten partial remissions. The response rate in 25 
previously untreated patients without brain métastasés was 40% (95% Cl 21-61%). Median duration of response was 6 (range 2-14J 
months; median overall survival was 5 (1-26) months. The main toxicity was malaise/fatigue. We confirm that BOLD plus IFN-a has activity 
in metastatic melanoma. The lower response rate in our study compared with the previous report is probably related to patient selection, 
as in the previous study 46% of patients had stage III disease, whereas all our patients had stage IV disease, which is associated with a 
worse prognosis.
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Although long-term remissions have been achieved in patients Falkson et al, 1996). Phase II results of DTIC plus IL-2 did not
with metastatic melanoma, the regimen of choice remains contro- suggest a clear benefit for this combination (Stoter et al, 1991;
versial in these patients. Single-agent therapy with dacarbazine Fiedler et al, 1992). High response rates of 42-73% have been
(DTIC) or immunotherapeutic agents such as interleukin 2 (IL-2) achieved in (mostly single centre) phase II studies with combina-
and interferon-a (IFN-a) results in response rates of 15-20% tions of IL-2, IFN-a and cisplatin (Khayat et al, 1993), IL-2, IFN-
(Houghton et al, 1992; Kirkwood, 1995; Marineóla and Rosenberg, a  and. CVD (Buzaid and Legha, 1994), IL-2, cisplatin, DTIC and
1995). With combination chemotherapy regimens, such as tamoxifen (Atkins et al, 1994), and IL-2, IFN-a, cisplatin, carmus-
cisplatin, vinblastine and DTIC (CVD) (Legha et al, 1989) or tine, DTIC and tamoxifen (Richards et al, 1992). The median dura-
cisplatin, carmustine, DTIC and tamoxifen (Del Prete et al, 1984; tion of response and survival in these studies was reported to be up
McClay et al, 1992), response rates of 40-52% have been to 9 months and 14 months respectively.
observed. The response rate of 40% initially reported for Pyrhönen et al, (1992) reported a 62% response rate (95% confi-
bleomycin, vincristine, lomustine and DTIC (BOLD) (Seigler et al, dence limit 48-77%) with 13% complete responses in 45 patients
1980) was not confirmed by others (York and Foltz, 1988; upon combination treatment consisting of BOLD plus IFN-a. Two
Prudente Foundation Melanoma Study Group, 1989). Combination patients with stable disease and two with progressive disease
immunotherapy with IL-2 and IFN-a has not unequivocally responded when the administration of IFN-a was changed from a
weekly to an intermittent schedule. There was one toxic death, butimproved the results of either agent alone (Kirkwood, 1995) and 
was very toxic when administered at high doses (Kruit et al, 1994; 
Marineóla et al, 1995; Kruit et al, 1996). Several chemoim­
munotherapy schedules have been clinically tested. The results of 
DTIC plus IFN-a are conflicting, with most trials failing to show a 
benefit of the combination over DTIC alone (Falkson et al, 1991; 
Thompson et al, 1993; Bajetta et al, 1994; Mulder et al, 1994;
overall toxicity was acceptable. Given these promising results, we 
performed a confirmatory study with the same schedule in patients 
with metastatic melanoma.
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PATIENTS AND METHODS
Eligibility
Eligibility criteria included histologically proven metastatic
«
melanoma, not amenable to surgery, bidimensionally measurable 
disease, WHO performance status 0-2, age 18-75 years, pretreat­
ment with a maximum of one regimen containing < 1 drug of the 
proposed regimen, serum values of creatinine < 150 jumol 1 ',
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Table 1 Patients' characteristics Table 2 Grade 3/4 toxicity in 42 evaluable patients
Characteristics No. of patients
Total number of patients, men/women 
Primary melanoma of skin/uvea 
Median age, years (range)
WHO performance status 
0 
1 
2
Median serum LDH, U I-1 (range)
Prior therapy 
Systemic treatment 
IL-2 + IFN-a + cisplatin 
IL-2 + IFN-«
DTIC
Regional limb perfusion 
Radiotherapy 
Surgery for métastasés
Disease sites 
Lungs
Lymph nodes
Skin/subcutaneous
Liver
Brain
Bone
Other
No. of disease sites 
1 
2
3
4
5
43, 27/16 
42/1
58 (22-74)
13
18
12
369 (161-4768)
7 
3 
2 
2 
1
8 
9
24
24
22
17
9
5
10
8
13
11
5
6
bilirubin ¿ 2 5  p.mol H , liver transaminases < 1.5 times normal 
unless related to liver métastasés, WBC >3.5 x 109 1 1 and 
platelets > 100 x 10y H. Patients with a history of second malig­
nancy, with the exception of adequately treated carcinoma in situ 
of the cervix or basal/squamous cell carcinoma of the skin, 
concomitant serious non-malignant , active infections, 
concurrent treatment with immunosuppressive agents and preg­
nant or lactating women were excluded. Patients with asympto­
matic brain métastasés were eligible provided they were not 
receiving treatment with steroids. Written informed consent was 
obtained from all patients. Before initiation of this trial, institu­
tional review board approval was obtained at each of the
•  *participating centres.
Study design
Patients were treated as outpatients with chemotherapy (BOLD) 
consisting of lomustine 80 mg administered orally on day 1, DTIC 
200 mg n r 2 i.v. on days 1-5, bleomycin 15 mg i.v. on days 2 + 5, 
and vincristine 1 mg n r 2 i.v. on days 1 + 4. Cycles were repeated 
every 4 weeks. IFN-a-2b (Intron A, Schering Plough, The 
Netherlands) was administered s.c. at 3 MU daily for 6 weeks 
starting at day 8 and 6 MU t.i.w. thereafter. Patients received
Toxicity Grade 3 Grade 4 Total no. of patients (%)
Malaise/fatigue 14 14 (33)
Alopecia 9 9(21)
Anorexia 6 6(14)
Nausea 5 0 5(12)
Vomiting 1 0 1 (2)
Lung 1 0 1(2)
Neuropsychiatrie 1 0 1(2)
Stomatitis 0 1 1(2)
Diarrhoea 1 0 1 (2)
Myalgia 1 1(2)
Leucocytopenia 8 0 8(19)
Anaemia 2 0 2(5)
Thrombocytopenia 1 0 1 (2)
Death *)« 1 (2)
m m
Toxicity according to WHO criteria: 1, mild; 2, moderate; 3, severe; 4, life- 
threatening. Numbers are patients. “Sudden death on fifth day of first cycle 
a causal relationship with treatment was unclear.
250 mg for constitutional by IFN-a was
allowed. Patients were evaluated weekly lor toxicity and every 
two cycles for response. WHO criteria for toxicity and response 
were used. Treatment was continued in the absence of tumour 
progression or severe toxicity. In the case of WHO grade 3 toxici­
des, treatment was withheld until complete resolution of the toxi­
city, and the dose of the responsible drug was reduced to 75% in 
subsequent cycles. Chemotherapy cycles were only restarted when 
WBC and platelet values were > 3.5 x 10<J I 1 and 100 x 101’ 1 1 
respectively. In the case of WHO > grade 3 vincristine-induced 
neurotoxicity or bleomycin-induced pulmonary toxicity, these 
drugs were permanently discontinued. A 50% dose reduction of 
IFN-a was allowed for > grade 3 constitutional symptoms.
RESULTS
Forty-three patients were entered onto the study in seven different 
centres. Patients’ characteristics are listed in Table 1. All patients 
had stage IV disease, i.e. with distant métastasés. The median age 
of all patients was 58 years (range 22-74), mediati WHO perfor­
mance status 1 (0-2), median serum lactate dehydrogenase (LDH) 
369 U 1 ' (161-4768, normal values up to 330 U I '). The median 
number of metastatic sites was 3 (1-5). The sites of métastasés 
were the lungs in 24 patients, lymph nodes in 24, skin/subcuta­
neous in 22, liver in 17, brain in nine, bone in five and other sites 
in ten patients. Visceral métastasés were present in 81% of 
patients. Seven patients had received prior systemic treatment, 
eight had received prior radiotherapy and nine had had surgery 
for métastasés. Patients received a median number of two (range 
1-8) cycles.
Anti-tumour responses
Two patients were not evaluable for response. One patient died 
suddenly on the fifth day of treatment and one patient refused 
treatment after one cycle and was subsequently lost to follow-up.
prophylactic antiemesis with 5HT} antagonists during the 5 days Thus, 41 patients were evaluable for response. The overall
of chemotherapy administration. The use of corticosteroids was
prohibited. Before and IFN-a administration, patients
received acetaminophen 1000 mg orally. The addition of naproxen
response rate was 27% (95% Cl 14-43%) with one CR and ten 
PRs. No responses occurred in the seven patients who had been 
systemically pretreated. Of the nine patients with brain métastasés,
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one PR occurred in a patient who had received prior cranial irradi- of IFN-a differed in the two studies. We used recombinant IFN-a-
ation, whereas all four patients with asymptomatic brain meta- 2b whereas Pyrhönen et al, used purified human leucocyte IFN-a
stases who were not previously irradiated progressed at this site. from the Finnish Red Cross Blood Transfusion Service (Cantell et
The response rate in 25 previously systemically untreated patients al, 1981). However, a clinical advantage for a specific type ol'IFN-
without brain métastasés was 40% (95% Cl 21-61 %). Responses a  has never been demonstrated. Second, there are important differ-
occurred in the lungs, skin/subcutaneous, lymph nodes, liver, enees between the patient populations of the two studies. In the
spleen, and adrenal métastasés. Median response duration was 6 study of Pyrhönen et al, (1992), 22 of the 48 patients (46%) had
months (range 2-14+ months). Median overall survival was 5 stage III disease, whereas all our patients had stage IV disease. For
months ( 1-26), and in the 25 patients without prior systemic treat- stage III melanoma patients with regional lymph node métastasés,
ment and brain métastasés 6 months (1-26). In four patients with surgery with regional radical lymphadenectomy is the treatment of
progressive disease the BOLD regimen was continued, but IFN-a choice, and for patients with intransit métastasés of an extremity
was given intermittently in 2-week periods interrupted by a isolated limb perfusion is preferred. For therapeutic groin dissec-
2-week rest period. In contrast to the original report (Pyrhönen tions in stage III patients, 5-year survival rates of 30-47%) have
et al, 1992), no responses or disease stabilizations were seen in 
these patients.
been reported, depending on the involvement of deep nodes (Kara- 
kousis et al, 1986). In the worst group of stage III patients, i.e. with
both regional node and in-transit métastasés, the 5-year survival
Clinical toxicities
Forty-two patients were evaluable for toxicity. Grade 3/4 toxicity
may be 19% and the median survival time 17 months (Singletary 
and Balch, 1992). This is in contrast to stage IV patients with non- 
visceral and visceral métastasés, who may have a 1 -year-survival
(WHO) occurred in 28 (67%) patients and consisted mainly of rate of 46% and 18% respectively and median survival times of
fatigue (33%), anorexia (14%), leucocytopenia (19%) and nausea 8 and 3 months respectively (Balch et al, 1992). Furthermore,
(12%) (Table 2). A 72-year-old man with a partial response of lung 71% of our patients had a WHO performance status of < 1,
métastasés and a complete response of liver, subcutaneous and whereas this was the case for 92% of patients in the study by
lymph node métastasés developed pulmonary fibrosis with dys- Pyrhönen et al (1992). Another aspect associated with poor prog-
pnoea at rest after the third chemotherapy cycle. Treatment was nosis was the median number of three metastatic sites in patients
discontinued and treatment with corticosteroids was instituted, 
after which his condition remained stable. He died 6 months later 
of brain métastasés. A 59-year-old female patient with a partial
from our study, and in a previous review no patients with this char­
acteristic survived for more than 1 year (Balch et al, 1992). It can 
therefore be concluded that our patient population consisted of a
response of lung métastasés experienced a severe depression, group with a worse prognosis than those in the study by Pyrhönen
which was quickly reversible after discontinuation of IFN-a. et al (1992). In that study, 10% of patients had brain métastasés
BOLD was continued for a total of six cycles. She died after 20 and several patients had been systemically pretreated. The median
months of tumour progression. A 67-year-old man died suddenly duration of response was not different between the two studies,
at home on the fifth day of the first chemotherapy cycle before being 6 months in our study and 6.8 months in the study of
treatment with IFN-a was initiated. A tentative diagnosis of a Pyrhönen et al (1992). Although tested in only four patients, we
myocardial infarction was made, and a definite causal relationship could not observe any disease regression in non-responders upon
with treatment could not be established. Toxicity necessitated dose changing the IFN -a administration to an intermittent schedule
reductions or discontinuation of BOLD chemotherapy in 16 out of (Pyrhönen et al, 1992).
134 cycles (12%) in eight patients (19%), and chemotherapy was The most common severe toxicity in our study was IFN-a-
delayed in 12 out of 134 cycles (9%) in ten patients (24%). The related malaise and fatigue, which occurred in 33% of patients,
dose of IFN-a was reduced or discontinued in six patients (14%). This occurred in 20% of patients in the study by Pyrhönen et al,
DISCUSSION
The mechanisms underlying the supposed synergistic interaction
(1992). Surprisingly, patients in this last study e 
grade 3/4 haematological toxicity than in oui 
cytopenia and ind 2% vs 32%) and 11 %
respectively). Whether this reflects the difference in the source of
between chemotherapy and immunotherapy are still speculative. 
Arguments for the enhancement of the anti-tumour activity of 
immunotherapy by chemotherapy as well as vice versa have been 
postulated. Clinical support for an interaction between these treat­
ment modalities comes from the observation that the sequence 
of administration of these treatment modalities appears to be 
an important factor (Buzaid and Legha, 1994). Furthermore, 
increasing CD4/CD8 ratios during chemoimmunotherapy with 
BOLD plus IFN-a have been correlated with response, implying 
the stimulation of host defence mechanisms (Hemberg et al, 
1996). The response rate with BOLD plus IFN-a in patients with 
metastatic melanoma in our study of 27% (95% Cl 14-43%) for
IFN-a is uncertain.
In conclusion, we confirm that BOLD plus IFN-a is an active 
regimen in patients with metastatic melanoma. The previous 
reported high response rate of 62% in 48 patients is probably 
related to a selection of patients with good prognosis. The median 
survival of 6 months in this group of patients is disappointing but 
may be related to poor prognostic parameters.
To date, the combination of immunotherapy (IFN-a and/or IL- 
2) with multidrug chemotherapy (mostly including DTIC and 
cisplatin) has yielded the highest response rates in metastatic 
melanoma, with response rates up to 70% (Pyrhönen et al, 1992; 
Richards et al, 1992; Khayat et al, 1993; Atkins et al, 1994; Buzaid
all patients and 40% (95% CI 21-61%) for patients without prior and Legha, 1994). However, all these results were obtained in
systemic treatment and brain métastasés are lower than reported 
by Pyrhönen et al, ( 1992), who used the same doses and schedule. 
This difference might be explained by two factors. First, the source
(mostly single centre) phase II studies. Recently, it has been 
demonstrated in the setting of a randomized phase 111 trial in 
metastatic melanoma that the addition of cisplatin to a regimen of
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IL-2 and IFN-a significantly increases the response rate Without Karakousis CP, Emrich U  and Rao U (1986) Groin dissection in malignant 
prolonging survival (Keilholz et al, 1996). In order to provide 
patients with metastatic melanoma with the best possible care, 
further randomized phase III trials are warranted to establish the 
value of combination treatments vs less intensive and therefore 
less toxic regimens.
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